Roivant Sciences ROIV
Nasdaq · Pharmaceutical Preparations · $28.0BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2026, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M | −71.6% | −37.8% | |
| Research & Development (R&D) | $483.0M | $454.1M | $439.9M | $550.4M | $681.8M | +23.9% | +9.0% | |
| Selling, General & Admin (SG&A) | $775.0M | $600.5M | $687.4M | — | $687.4M | — | −3.0% | |
| Total Operating Expenses | $1.4B | $938.3M | $884.1M | $1.1B | $1.3B | +13.2% | −2.1% | |
| Operating Income (EBIT) | $-1.4B | $-906.8M | $4.5B | $-1.0B | $-515.1M | +48.7% | — | |
| Interest Expense | $7.0M | $28.0M | $34.8M | — | $34.8M | — | +49.1% | |
| Income Tax Expense | $369,000 | $4.1M | $21.5M | $48.2M | $133.3M | +176.8% | +336.0% | |
| GAAP Net Income | $-845.3M | $-1.0B | $4.3B | $-172.0M | $-299.8M | −74.3% | — | |
| Diluted EPS | $-1.26 | $-1.42 | $5.23 | $-0.24 | $-0.54 | −125.0% | — | |
| Diluted Shares | 669.8M | 712.8M | 831.0M | 725.4M | 693.9M | −4.3% | +0.9% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $2.1B | $1.7B | $6.5B | $2.7B | $1.4B | −47.5% | −8.9% | |
| Inventory | $0 | $2.8M | $35.3M | $34.0M | $34.0M | +0.0% | — | |
| Total Current Assets | $2.1B | $1.8B | $6.7B | $5.0B | $5.2B | +3.3% | +24.6% | |
| Total Assets | $2.6B | $2.4B | $7.2B | $5.4B | $5.7B | +5.0% | +21.9% | |
| Total Current Liabilities | $184.4M | $272.4M | $266.8M | $149.4M | $281.2M | +88.2% | +11.1% | |
| Total Debt (Short + Long Term) | $210.0M | $416.2M | $442.6M | $323.7M | $323.7M | +0.0% | +11.4% | |
| Total Liabilities | $523.7M | $782.0M | $774.0M | $249.7M | $416.3M | +66.7% | −5.6% | |
| Stockholders' Equity | $2.0B | $1.6B | $6.4B | $5.2B | $5.3B | +2.0% | +26.9% | |
| Net Cash / (Net Debt) | $1.9B | $1.3B | $6.1B | $2.4B | $1.1B | −53.9% | −12.2% | |
| Invested Capital | $174.9M | $331.7M | $384.9M | $2.8B | $4.2B | +50.3% | +121.2% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $-677.7M | $-843.4M | $-765.3M | $-839.5M | $-750.3M | +10.6% | — | |
| Depreciation & Amortization (D&A) | $5.9M | $18.9M | $22.0M | $14.1M | $3.3M | −76.2% | −13.3% | |
| Stock-Based Compensation (SBC) | $565.0M | $217.8M | $199.6M | $289.0M | $346.2M | +19.8% | −11.5% | |
| Capital Expenditures (CapEx) | $17.4M | $12.7M | $1.4M | $4.6M | $8.2M | +78.5% | −17.2% | |
| Free Cash Flow (FCF) | $-695.2M | $-856.1M | $-766.6M | $-844.0M | $-758.6M | +10.1% | — | |
| True FCF (ex-SBC Owner Cash) | $-1.3B | $-1.1B | $-966.3M | $-1.1B | $-1.1B | +2.5% | — | |
| Share Repurchases (Buybacks) | — | $0 | $0 | $1.3B | $1.3B | +0.0% | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.